Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 9,618 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,473 shares of the biopharmaceutical company's stock after selling 9,618 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned about 0.09% of Regeneron Pharmaceuticals worth $56,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the period. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Franklin Resources Inc. increased its stake in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after purchasing an additional 149,124 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN remained flat at $521.00 during midday trading on Friday. 1,607,735 shares of the company were exchanged, compared to its average volume of 897,423. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a 50-day simple moving average of $555.02 and a 200 day simple moving average of $634.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a market capitalization of $56.25 billion, a PE ratio of 13.26, a P/E/G ratio of 1.91 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $9.55 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on REGN shares. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday, June 2nd. Finally, Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.